Search - tctmd.com

Displaying 1 - 20 of 60

Sort: Relevancy | Date

News Daily News

Nearly 150 Million US Adults Eligible for CKM Syndrome Meds

Caitlin E. Cox

February 02, 2026

News Daily News

Year in Review: Top Prevention Stories of 2025

Michael O'Riordan

December 24, 2025

News Opinion CV Team Dispatch

October 2025 Dispatch for the CV Team

L.A. McKeown

October 25, 2025

News Daily News

Glipizide, Commonly Used Sulfonylurea, Linked to Greater CV Risks

Michael O'Riordan

August 01, 2025

News Daily News

Weight-Loss Medications Should Be Part of Cardiology’s Arsenal: ACC

Michael O'Riordan

June 25, 2025

News Daily News

Amylin Analogue Boosts Weight Loss When Added to GLP-1

L.A. McKeown

June 24, 2025

Obesity-Related Cancer Rates No Different With GLP-1s vs Bariatric Surgery

Michael O'Riordan

May 14, 2025

News Conference News European Congress on Obesity 2025

SELECT: Semaglutide’s Impact on CVD Events Emerges Quickly

Michael O'Riordan

May 14, 2025

News Conference News European Congress on Obesity 2025

Tirzepatide Tops Semaglutide for Weight Loss: SURMOUNT-5

Michael O'Riordan

May 12, 2025

News Daily News

Medicaid Patients With Type 2 Diabetes Face Hurdles Getting Cardioprotective Meds

Michael O'Riordan

April 25, 2025

News Daily News

US Football Fans Are Flooded With Ads for Unhealthy Foods

Michael O'Riordan

January 30, 2025

News Opinion CV Team Dispatch

January 2025 Dispatch for the CV Team

L.A. McKeown

January 24, 2025

News Daily News

Misleading Statements Common in Online Ads for Compounded GLP-1s

L.A. McKeown

January 20, 2025

News Daily News

Variety of GLP-1 Drugs Help People Without Diabetes Lose Weight: Review

Todd Neale

January 09, 2025

News Daily News

Tirzepatide Gets FDA Approval for Sleep Apnea in Adults With Obesity

L.A. McKeown

December 23, 2024

News Daily News

Tirzepatide Bests Semaglutide for Weight Loss: SURMOUNT-5 Top-line Results

Michael O'Riordan

December 04, 2024

SUMMIT: Tirzepatide ‘Huge Win’ for HFpEF Patients With Obesity

News Conference News AHA 2024

SUMMIT: Tirzepatide a ‘Huge Win’ for HFpEF Patients With Obesity

Michael O'Riordan

November 16, 2024

News Daily News

SOUL: Oral Semaglutide Cuts CV Events in Diabetic Patients

L.A. McKeown

October 23, 2024

News Daily News

Defying Earlier GLP-1 Data, Study in Teens Sees Possible Mental Health Gains

L.A. McKeown

October 22, 2024

News Daily News

Cheaper Version of Tirzepatide for Weight Loss Now Available, Lilly Says

Caitlin E. Cox

August 28, 2024

Advertisement

Nearly 150 Million US Adults Eligible for CKM Syndrome Meds

Year in Review: Top Prevention Stories of 2025

October 2025 Dispatch for the CV Team

Glipizide, Commonly Used Sulfonylurea, Linked to Greater CV Risks

Weight-Loss Medications Should Be Part of Cardiology’s Arsenal: ACC

Amylin Analogue Boosts Weight Loss When Added to GLP-1

Obesity-Related Cancer Rates No Different With GLP-1s vs Bariatric Surgery

SELECT: Semaglutide’s Impact on CVD Events Emerges Quickly

Tirzepatide Tops Semaglutide for Weight Loss: SURMOUNT-5

Medicaid Patients With Type 2 Diabetes Face Hurdles Getting Cardioprotective Meds

US Football Fans Are Flooded With Ads for Unhealthy Foods

January 2025 Dispatch for the CV Team

Misleading Statements Common in Online Ads for Compounded GLP-1s

Variety of GLP-1 Drugs Help People Without Diabetes Lose Weight: Review

Tirzepatide Gets FDA Approval for Sleep Apnea in Adults With Obesity

Tirzepatide Bests Semaglutide for Weight Loss: SURMOUNT-5 Top-line Results

SUMMIT: Tirzepatide a ‘Huge Win’ for HFpEF Patients With Obesity

SOUL: Oral Semaglutide Cuts CV Events in Diabetic Patients

Defying Earlier GLP-1 Data, Study in Teens Sees Possible Mental Health Gains

Cheaper Version of Tirzepatide for Weight Loss Now Available, Lilly Says

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content